Bessemer Group Inc. increased its position in shares of Haemonetics Corporation (NYSE:HAE) by 5.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 57,600 shares of the company’s stock after buying an additional 2,900 shares during the period. Bessemer Group Inc.’s holdings in Haemonetics Corporation were worth $2,316,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Rutabaga Capital Management LLC MA bought a new stake in shares of Haemonetics Corporation during the second quarter worth about $17,805,000. American Capital Management Inc. purchased a new position in shares of Haemonetics Corporation during the third quarter worth $20,732,000. Victory Capital Management Inc. increased its position in shares of Haemonetics Corporation by 34.0% in the third quarter. Victory Capital Management Inc. now owns 1,963,684 shares of the company’s stock worth $71,105,000 after buying an additional 497,834 shares during the last quarter. Panagora Asset Management Inc. increased its position in shares of Haemonetics Corporation by 237.3% in the third quarter. Panagora Asset Management Inc. now owns 495,202 shares of the company’s stock worth $17,931,000 after buying an additional 348,391 shares during the last quarter. Finally, BlackRock Fund Advisors increased its position in shares of Haemonetics Corporation by 8.6% in the third quarter. BlackRock Fund Advisors now owns 3,616,662 shares of the company’s stock worth $130,959,000 after buying an additional 284,894 shares during the last quarter. 99.43% of the stock is currently owned by hedge funds and other institutional investors.
Haemonetics Corporation (NYSE:HAE) opened at 37.91 on Wednesday. The company has a market cap of $1.97 billion, a PE ratio of 120.73 and a beta of 0.92. The firm’s 50-day moving average price is $39.46 and its 200 day moving average price is $37.63. Haemonetics Corporation has a 52-week low of $25.98 and a 52-week high of $41.65.
Haemonetics Corporation (NYSE:HAE) last released its earnings results on Monday, February 6th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.40 by $0.03. The company earned $227.80 million during the quarter, compared to analyst estimates of $220 million. Haemonetics Corporation had a return on equity of 10.51% and a net margin of 1.79%. Haemonetics Corporation’s quarterly revenue was down 2.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.48 earnings per share. On average, equities analysts predict that Haemonetics Corporation will post $1.52 EPS for the current fiscal year.
This piece of content was originally reported by sleekmoney and is the sole property of of sleekmoney. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The legal version of this piece of content can be viewed at http://sleekmoney.com/bessemer-group-inc-acquires-2900-shares-of-haemonetics-corporation-hae/1662277.html.
HAE has been the subject of a number of analyst reports. Zacks Investment Research downgraded shares of Haemonetics Corporation from a “buy” rating to a “hold” rating in a research report on Thursday, January 5th. Benchmark Co. lifted their price target on Haemonetics Corporation from $32.00 to $34.00 and gave the stock a “hold” rating in a report on Monday, November 7th. Barrington Research downgraded Haemonetics Corporation from an “outperform” rating to a “market perform” rating in a research report on Tuesday, February 7th. Finally, BTIG Research restated a “neutral” rating on shares of Haemonetics Corporation in a research note on Monday, November 7th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $34.57.
In other news, Director Ronald G. Gelbman sold 5,683 shares of the firm’s stock in a transaction on Monday, December 12th. The stock was sold at an average price of $40.30, for a total transaction of $229,024.90. Following the completion of the sale, the director now directly owns 49,688 shares of the company’s stock, valued at approximately $2,002,426.40. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.50% of the stock is currently owned by insiders.
Haemonetics Corporation Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/bessemer-group-inc-acquires-2900-shares-of-haemonetics-corporation-hae/1662277.html
Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.